Weight loss and diabetes drugs bring in more than 60% of Lilly's revenue, and Forbes looks at where the CEO is putting billions next.
Recap by typeshit. Full story at Forbes.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Nacionale covers research into whether GLP-1 drugs have effects reaching into criminal justice outcomes and how steadily people stay employed.
A Facebook post reports the TRIUMPH-2 result for Lilly's triple agonist in people with type 2 diabetes. Few details beyond the headline number are given.
Loading…